Literature DB >> 27013652

Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.

Megan Othus1, Wim van Putten2, Bob Lowenberg2, Stephen H Petersdorf3, Sucha Nand4, Harry Erba5, Frederick Appelbaum6, Robert Hills7, Nigel Russell8, Alan Burnett7, Elihu Estey6.   

Abstract

Entities:  

Keywords:  acute myeloid leukemia; endpoint; surrogacy

Mesh：

Year:  2016        PMID： 27013652      PMCID： PMC5004473          DOI： 10.3324/haematol.2015.138552

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

Authors:  Mohamed L Sorror; Rainer F Storb; Brenda M Sandmaier; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Smita Bhatia; Fabiana Ostronoff; H Joachim Deeg; Karen L Syrjala; Elihu Estey; David G Maloney; Frederick R Appelbaum; Paul J Martin; Barry E Storer
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

2.  Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.

Authors:  Alan K Burnett; Anthony Goldstone; Robert K Hills; Donald Milligan; Archie Prentice; John Yin; Keith Wheatley; Ann Hunter; Nigel Russell
Journal:  J Clin Oncol       Date:  2013-02-25       Impact factor: 44.544

3.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

4.  Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.

Authors:  Marc Buyse; Stefan Michiels; Pierre Squifflet; Kathryn J Lucchesi; Kristoffer Hellstrand; Mats L Brune; Sylvie Castaigne; Jacob M Rowe
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

5.  A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.

Authors:  Sucha Nand; Megan Othus; John E Godwin; Cheryl L Willman; Thomas H Norwood; Dianna S Howard; Steven E Coutre; Harry P Erba; Frederick R Appelbaum
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

6.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

7.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Authors:  Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

8.  U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.

Authors:  Thomas M Herndon; Suzanne G Demko; Xiaoping Jiang; Kun He; Joseph E Gootenberg; Martin H Cohen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2012-09-21

9.  FDA drug approval summary: panitumumab (Vectibix).

Authors:  Ruthann M Giusti; Kaushikkumar A Shastri; Martin H Cohen; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2007-05

10.  Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Authors:  Stefan Faderl; Meir Wetzler; David Rizzieri; Gary Schiller; Madan Jagasia; Robert Stuart; Siddhartha Ganguly; David Avigan; Michael Craig; Robert Collins; Michael Maris; Tibor Kovacsovics; Stuart Goldberg; Karen Seiter; Parameswaran Hari; Jochen Greiner; Norbert Vey; Christian Recher; Farhad Ravandi; Eunice S Wang; Michael Vasconcelles; Dirk Huebner; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544
View more
  5 in total

1.  Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).

Authors:  Jun Yin; Betsy LaPlant; Geoffrey L Uy; Guido Marcucci; William Blum; Richard A Larson; Richard M Stone; Sumithra J Mandrekar
Journal:  Blood Adv       Date:  2019-06-11

Review 2.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

3.  Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Authors:  Roland B Walter; Laura C Michaelis; Megan Othus; Geoffrey L Uy; Jerald P Radich; Richard F Little; Sandi Hita; Lalit Saini; James M Foran; Aaron T Gerds; Heidi D Klepin; Annette E Hay; Sarit Assouline; Jeffrey E Lancet; Stephen Couban; Mark R Litzow; Richard M Stone; Harry P Erba
Journal:  Am J Hematol       Date:  2017-12-04       Impact factor: 10.047

Review 4.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

5.  Clinical value of event-free survival in acute myeloid leukemia.

Authors:  Abhishek Maiti; Hagop M Kantarjian; Vinita Popat; Gautam Borthakur; Guillermo Garcia-Manero; Marina Y Konopleva; Courtney D DiNardo; Srdan Verstovsek; Michael Andreeff; Tapan M Kadia; Helen O Ajufo; Rohit V Goswamy; Carlos Blanco; Miguel Velasquez; Naval G Daver; Naveen Pemmaraju; Sherry R Pierce; William G Wierda; Steven M Kornblau; Farhad Ravandi; Jorge E Cortes
Journal:  Blood Adv       Date:  2020-04-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.